Clinical outcomes of flomoxef versus cefmetazole in hospitalized patients with urinary tract infections: Combined retrospective analyses of two real-world databases andin vitrodata

Abstract

AbstractBackgroundFlomoxef is active against extended-spectrum beta-lactamase (ESBL)-producing bacteria, but its clinical effectiveness has not been compared with cefmetazole. This study aimed to compare the utility of the two drugs in treating urinary tract infection (UTI) by integratingin vitrodata with a retrospective analysis of two real-world databases.MethodsThe susceptibility rates of third-generation cephalosporin-resistantEscherichia coliandKlebsiella pneumoniaeto flomoxef and cefmetazole were compared using comprehensive national antimicrobial resistance surveillance data. Combinational antimicrobial activities against an ESBL-producing multidrug-resistant bacterial strain were tested by diagonal measurement of n-way drug interactions (DiaMOND), an innovative method to assess antimicrobial interactionsin vitro. The effectiveness of the two drugs in treating UTIs was compared using hospital stay duration as the primary outcome obtained from the Japan Medical Data Center (JMDC) Claims Database.ResultsThird-generation cephalosporin-resistantE. coliandK. pneumoniae, including ESBL-producing strains, were similarly susceptible to flomoxef and cefmetazole.In vitroassessment of combinational antimicrobial activities against an ESBL-producing multidrug-resistant strain revealed that both drugs showed similar antimicrobial interaction patterns.JMDC Claims data analysis showed that the median time of hospital stay duration was 11 days (95% confidence interval [CI]: 11–11) in the cefmetazole group and 4 days (95% CI: 3– 5) in the flomoxef group, significantly shorter in the latter (log-rank test, P < 0.001). In addition, the flomoxef group had a significantly lower frequency of adverse events such asClostridioides difficileinfection.ConclusionsFlomoxef exhibits effectiveness that is comparable to cefmetazole in treating UTI without major concerns about adverse events such asC. difficileinfection or renal impairment. This evidence endorses flomoxef as a viable treatment option for UTIs in locales with high prevalence of ESBL-prodcing strains.Key PointsAn oxacephem antimicrobial agent, flomoxef, exhibited effectiveness comparable to cefmetazole in the treatment of urinary tract infections and was superior in terms of safety.